Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

10/20/2021 | 06:38pm EST

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendation from the FDA'sVaccines and Related Biological Products Advisory Committee (VRBPAC) based on data provided by the Company, including efficacy, safety and immunogenicity data from its clinical trials and real-world evidence data. When administered as a primary or booster dose, following initial vaccination with the Company's COVID-19 single-shot vaccine, it provided protection against symptomatic disease and was generally well-tolerated, highlighting the favorable benefit-risk profile of a booster dose in light of the ongoing pandemic. A single booster dose of the Johnson & Johnson COVID-19 vaccine may also be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) will provide a potential recommendation on October 21. In the U.S., there is sufficient supply to support boosting to those who have received the Johnson & Johnson COVID-19 vaccine. More than 15.2 million doses of the Company's COVID-19 vaccine have been administered as primary vaccinations in the U.S.

ę S&P Capital IQ 2021
All news about JOHNSON & JOHNSON
02:41pJohnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
10:21aZymeworks to Get Milestone Payment After Janssen Doses First Patient With Licensed Anti..
09:34aJohnson & Johnson announces significant progress towards its climate goals - 100% renew..
11/30JOHNSON & JOHNSON : Janssen Seeks Approval of IMBRUVICA«(ibrutinib) in a Fixed-Duration Re..
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
11/30Johnson & Johnson Units, Aspen Pharmacare Sign Term Sheet for Manufacturing of COVID-19..
11/30JOHNSON & JOHNSON : Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced St..
11/30JOHNSON & JOHNSON : announces significant progress towards its climate goals – 100% ..
11/30JOHNSON & JOHNSON : How Johnson & Johnson is Working to Create a Healthier Planet
11/30Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 18,8x
Yield 2021 2,67%
Capitalization 411 B 411 B -
EV / Sales 2021 4,36x
EV / Sales 2022 4,05x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 155,93 $
Average target price 184,65 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ABBVIE INC.7.59%203 801